SCHEMBL3163370

SCHEMBL3163370

O=C(NCc1cccc(C(F)(F)F)c1)c1ccc(S(=O)(=O)Nc2ncc(Cl)s2)cc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 1/20 0.58
MAPT P10636 3/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
HTT P42858 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
LMNA P02545 3/20 0.48
HPGD P15428 1/20 0.48
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46
ATG4B Q9Y4P1 2/20 0.46
RAB9A P51151 1/20 0.46
PLA2G1B P04054 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
GAA P10253 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CCR1 P32246 6/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3159771 0.91 SCN3A (0.63) SCN3AMAPTMEN1KMT2AHTT
SCHEMBL3164340 0.88 SCN3A (0.75) SCN3AMAPTMEN1KMT2AHTT
SCHEMBL3162846 0.88 SCN3A (0.54) SCN3ASCN9A
SCHEMBL3160204 0.87 SCN3A (0.66) SCN3AMAPTMEN1KMT2ASCN9A
SCHEMBL3161075 0.87 SCN3A (0.69) SCN3AMAPTMEN1KMT2AHTT
SCHEMBL3171535 0.86 SCN3A (0.59) SCN3AMEN1KMT2ASCN9A
SCHEMBL3158722 0.85 SCN3A (0.63) SCN3AMEN1KMT2ASCN9A
SCHEMBL3154361 0.85 SCN3A (0.63) SCN3AMEN1KMT2ASCN9A
SCHEMBL3169451 0.84 SCN3A (0.61) SCN3AMAPTMEN1KMT2AHTT
SCHEMBL3173419 0.83 SCN3A (0.57) SCN3ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN3A 13/4885MAPT 2938/4885MEN1 4729/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN3A 13/4885MAPT 2938/4885MEN1 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.